News

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

MACs categorize goniotomy, canaloplasty, cyclophotocoagulation as experimental; glaucoma specialists speak out.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

Patients considered vitamin D deficient had a risk of noninfectious uveitis more than twice that of their counterparts without vitamin D deficiency.

Investigators pointed out that spondyloarthritis (SpA) and Behçet’s disease are typical diseases that require the expertise of rheumatologists and ophthalmologists.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

Experts from around the globe converged in San Francisco, California

According to the company, its RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe dry eye disease, and further explore the potential of a genetic biomarker. Topline results are expected in mid-2024.

Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD.

Fish have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.

Some animals have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.

The company says top-line efficacy and safety data is on track for release in December of 2023.

Restoration and regeneration represent a new paradigm

According to the company, ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

Sanjib Kumar Kar, MBBS, MD, was caught taking a bribe of ₹5,500 (~$65 USD) from a complainant to conduct surgery on his uncle.

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).